Pan‐HSP90 ligand binding reveals isoform‐specific differences in plasticity and water networks

Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA‐approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Protein science Ročník 32; číslo 5; s. e4629 - n/a
Hlavní autoři:	Stachowski, Timothy R., Nithianantham, Stanley, Vanarotti, Murugendra, Lopez, Karlo, Fischer, Marcus
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Hoboken, USA John Wiley & Sons, Inc 01.05.2023 Wiley Subscription Services, Inc
Témata:	Antineoplastic Agents - chemistry Binding conformational flexibility Heat shock proteins HSP90 Heat-Shock Proteins - chemistry Hsp90 isoforms Hsp90 protein Humans Isoforms ligand binding Ligands pan‐Hsp90 inhibitors Protein Binding Protein Conformation Protein folding Protein Isoforms - chemistry Proteins Side effects Therapeutic targets water networks Hsp90 isoforms conformational flexibility pan-Hsp90 inhibitors water networks ligand binding
ISSN:	0961-8368, 1469-896X, 1469-896X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA‐approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan‐HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three‐pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side‐chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform‐ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an “old” target and reveal hidden isoform‐specific accommodations of congeneric ligands that may be exploited in ligand discovery and design. PDB Code(s): 7ULJ, 7ULL and 7ULK;
AbstractList	Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA‐approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan‐HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three‐pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side‐chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform‐ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an “old” target and reveal hidden isoform‐specific accommodations of congeneric ligands that may be exploited in ligand discovery and design. PDB Code(s): 7ULJ, 7ULL and 7ULK; Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA‐approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan‐HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three‐pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side‐chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform‐ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an “old” target and reveal hidden isoform‐specific accommodations of congeneric ligands that may be exploited in ligand discovery and design. PDB Code(s): 7ULJ , 7ULL and 7ULK ; Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA‐approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan‐HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three‐pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side‐chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform‐ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an “old” target and reveal hidden isoform‐specific accommodations of congeneric ligands that may be exploited in ligand discovery and design. PDB Code(s): 7ULJ, 7ULL and 7ULK; Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA‐approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan‐HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three‐pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side‐chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform‐ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an “old” target and reveal hidden isoform‐specific accommodations of congeneric ligands that may be exploited in ligand discovery and design. Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA-approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan-HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three-pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side-chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform-ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an "old" target and reveal hidden isoform-specific accommodations of congeneric ligands that may be exploited in ligand discovery and design.Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains unfulfilled as there is still no FDA-approved drug targeting HSP90 in disease. Among the reasons hindering progress are side effects caused by pan-HSP90 inhibition. Selective targeting of the four isoforms is challenging due to high sequence and structural similarity. Surprisingly, while decades of drug discovery efforts have produced almost 400 human HSP90 structures, no single ligand has been structurally characterized across all four human isoforms to date, which could reveal structural differences to achieve selectivity. To better understand the HSP90 landscape relevant for ligand binding and design we take a three-pronged approach. First, we solved the first complete set of structures of a single ligand bound to all four human isoforms. This enabled a systematic comparison of how side-chains and water networks respond to ligand binding across isoforms. Second, we expanded our analysis to publicly available, incomplete isoform-ligand series with distinct ligand chemistry. This highlighted general trends of protein and water mobility that differ among isoforms and impact ligand binding. Third, we further probed the Hsp90α conformational landscape for accommodating a congeneric series containing the purine scaffold common to HSP90 inhibitors. This revealed how minor ligand modifications flip ligand poses and perturb water and protein conformations. Taken together, this work illustrates how a systematic approach can shed new light on an "old" target and reveal hidden isoform-specific accommodations of congeneric ligands that may be exploited in ligand discovery and design.
Author	Nithianantham, Stanley Vanarotti, Murugendra Stachowski, Timothy R. Lopez, Karlo Fischer, Marcus
AuthorAffiliation	1 Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis Tennessee USA 2 School of Natural Sciences, Mathematics, and Engineering California State University Bakersfield California 93311 USA
AuthorAffiliation_xml	– name: 2 School of Natural Sciences, Mathematics, and Engineering California State University Bakersfield California 93311 USA – name: 1 Department of Chemical Biology and Therapeutics St. Jude Children's Research Hospital Memphis Tennessee USA
Author_xml	– sequence: 1 givenname: Timothy R. orcidid: 0000-0002-6097-4857 surname: Stachowski fullname: Stachowski, Timothy R. organization: St. Jude Children's Research Hospital – sequence: 2 givenname: Stanley orcidid: 0000-0001-6238-647X surname: Nithianantham fullname: Nithianantham, Stanley organization: St. Jude Children's Research Hospital – sequence: 3 givenname: Murugendra orcidid: 0000-0003-4355-0283 surname: Vanarotti fullname: Vanarotti, Murugendra organization: St. Jude Children's Research Hospital – sequence: 4 givenname: Karlo orcidid: 0000-0002-6613-6547 surname: Lopez fullname: Lopez, Karlo organization: California State University – sequence: 5 givenname: Marcus orcidid: 0000-0002-7179-2581 surname: Fischer fullname: Fischer, Marcus email: marcus.fischer@stjude.org organization: St. Jude Children's Research Hospital
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36938943$$D View this record in MEDLINE/PubMed
BookMark	eNp1kd1KHDEUgINY6qoFn6AM9Mab2SaTmUxyJUW0FgQXa6F3IZOcrNHZZJrMuuxdH6HP2Cdptlq10l6Fw_nOl_Ozi7Z98IDQAcFTgnH1fohhWrNKbKEJqZkouWBft9EEC0ZKThnfQbsp3WCMa1LR12iHMkG5qOkEdTPlf37_cfZ5JnDRu7nypuicN87Piwh3oPpUuBRsiIuMpQG0s04XxlkLEbyGnPbF0Ks0Ou3GdbERrNQIsfAwrkK8Tfvolc0aePPw7qEvpydXx2fl-cXHT8cfzktdUyFK6KzRYCgnhqqmIaQmxIJqDW0xJ50lzHDREaY5w5a1ttON1qIFI6Az1Bq6h47uvcOyW0B2-TGqXg7RLVRcy6Cc_Dvj3bWchztJMMG8pm02HD4YYvi2hDTKhUsa-l55CMskq5ZznuGmyei7F-hNWEaf55MVx4xj0dA6U2-ft_TYy5_9P_2oY0gpgn1ECJab0-Y4yM1pMzp9geZ9q9GFzTCu_1dBeV-wcj2s_yuWs8uL3_wvu164pQ
CitedBy_id	crossref_primary_10_1002_rcm_9960 crossref_primary_10_1107_S2052252525001332 crossref_primary_10_1002_pro_70082 crossref_primary_10_1038_s41592_025_02724_0 crossref_primary_10_3923_asb_2025_205_223 crossref_primary_10_1016_j_ejmech_2024_116934 crossref_primary_10_1002_slct_202403409 crossref_primary_10_3390_biology14050487
Cites_doi	10.1002/cmdc.200900011 10.1039/D0SC04938G 10.1073/pnas.2011350117 10.1021/acs.jmedchem.7b01608 10.1002/pro.423 10.1016/S0968-0004(02)02067-4 10.1021/acschembio.6b00747 10.1038/s41467-017-02013-1 10.1074/jbc.RA119.009960 10.1158/1078-0432.CCR-13-2571 10.1016/j.apsb.2020.11.015 10.1021/ja303477g 10.1107/S0907444912044423 10.1093/nar/28.1.235 10.7554/eLife.74114 10.1016/j.ejmech.2022.114516 10.1016/j.bmcl.2013.11.036 10.1021/ja511893n 10.1039/D1SC02751D 10.1002/chem.201703398 10.1002/anie.202112919 10.1002/jcc.20084 10.1021/jm500042s 10.1073/pnas.1703287114 10.1002/cbic.201500196 10.1074/jbc.M308661200 10.1124/mi.9.1.7 10.1016/j.tibs.2014.12.002 10.1107/S2059798319011471 10.2174/156802609789895737 10.1038/nature04716 10.7554/eLife.25235 10.1021/acs.jmedchem.2c00708 10.1021/jacs.9b06275 10.1107/S0021889807021206 10.2174/1568026616666160413141154 10.1107/S0907444909047337 10.1002/prot.25750 10.1038/nsmb.1565 10.1021/acschembio.5b00683 10.1007/978-3-030-40204-4_9 10.1007/128_2011_181 10.1016/S0076-6879(97)76066-X 10.1038/s41467-017-02258-w 10.1016/j.bbamcr.2011.09.003 10.1073/pnas.1500806112 10.1021/acs.jmedchem.8b00105 10.2174/1389450120666190829162544 10.1016/j.ejmech.2021.113604 10.1107/S0907444910007493 10.1017/S0033583520000128 10.1016/j.sbi.2015.07.003 10.1038/nchembio.1335 10.1021/jm060297x 10.1021/acs.jmedchem.0c01700 10.1021/jm200350g 10.1038/nrc2887 10.1002/anie.202015422 10.2174/138161213804143725 10.1016/j.jmb.2009.03.071 10.1016/bs.acr.2015.12.001 10.1021/acs.jmedchem.7b00057 10.1038/nrc1716 10.1021/acschembio.8b00443 10.1021/jm900357y
ContentType	Journal Article
Copyright	2023 The Authors. published by Wiley Periodicals LLC on behalf of The Protein Society. 2023 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society. 2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: 2023 The Authors. published by Wiley Periodicals LLC on behalf of The Protein Society. – notice: 2023 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society. – notice: 2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7T5 7TM 7U9 8FD FR3 H94 K9. P64 RC3 7X8 5PM
DOI	10.1002/pro.4629
DatabaseName	Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Immunology Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Biotechnology Research Abstracts Technology Research Database Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic
DatabaseTitleList	CrossRef Genetics Abstracts MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology Chemistry
DocumentTitleAlternate	Stachowski et al
EISSN	1469-896X
EndPage	n/a
ExternalDocumentID	PMC10108437 36938943 10_1002_pro_4629 PRO4629
Genre	article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: American Lebanese Syrian Associated Charities – fundername: National Institute of General Medical Sciences funderid: R35GM142772 – fundername: NIGMS NIH HHS grantid: R35 GM142772 – fundername: ; – fundername: ; grantid: R35GM142772
GroupedDBID	--- .GJ 05W 0R~ 123 1L6 1OC 24P 29P 2WC 31~ 33P 3SF 3WU 4.4 52U 53G 5RE 6TJ 8-0 8-1 8UM A00 A8Z AAESR AAEVG AAHHS AAHQN AAIHA AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABGDZ ABLJU ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACIWK ACPOU ACPRK ACQPF ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AUFTA AZVAB BFHJK BHBCM BMNLL BMXJE BNHUX BOGZA BRXPI C1A C45 CAG COF CS3 DCZOG DIK DRFUL DRSTM DU5 E3Z EBD EBS EJD EMOBN F5P G-S GODZA GX1 HGLYW HH5 HYE HZ~ IH2 LATKE LEEKS LITHE LOXES LUTES LYRES MEWTI MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM MY~ NNB O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ QRW RCA RIG ROL RPM RWI SJN SUPJJ SV3 TEORI TR2 WBKPD WIH WIK WIN WNSPC WOHZO WOQ WXSBR WYISQ WYJ XV2 Y6R YKV ZGI ZXP ZZTAW ~02 ~S- AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION LH4 CGR CUY CVF ECM EIF NPM 7QO 7T5 7TM 7U9 8FD ESTFP FR3 H94 K9. P64 RC3 7X8 5PM
ID	FETCH-LOGICAL-c4399-ebfdced381d3a5511411fea7d37081bf16d89b16c860f67fbc5cc97ed9ebd3fd3
IEDL.DBID	24P
ISICitedReferencesCount	7
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000973169800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0961-8368 1469-896X
IngestDate	Tue Sep 30 17:14:35 EDT 2025 Mon Sep 08 13:36:33 EDT 2025 Thu Dec 04 03:25:37 EST 2025 Mon Jul 21 06:04:03 EDT 2025 Tue Nov 18 20:59:31 EST 2025 Sat Nov 29 01:38:41 EST 2025 Wed Jan 22 16:23:18 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	Hsp90 isoforms conformational flexibility pan-Hsp90 inhibitors water networks ligand binding
Language	English
License	Attribution-NonCommercial 2023 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4399-ebfdced381d3a5511411fea7d37081bf16d89b16c860f67fbc5cc97ed9ebd3fd3
Notes	John Kuriyan Review Editor ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Review Editor: John Kuriyan
ORCID	0000-0002-6097-4857 0000-0002-7179-2581 0000-0002-6613-6547 0000-0001-6238-647X 0000-0003-4355-0283
OpenAccessLink	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpro.4629
PMID	36938943
PQID	2806809534
PQPubID	1016442
PageCount	17
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_10108437 proquest_miscellaneous_2788801055 proquest_journals_2806809534 pubmed_primary_36938943 crossref_primary_10_1002_pro_4629 crossref_citationtrail_10_1002_pro_4629 wiley_primary_10_1002_pro_4629_PRO4629
PublicationCentury	2000
PublicationDate	May 2023 2023-05-00 20230501
PublicationDateYYYYMMDD	2023-05-01
PublicationDate_xml	– month: 05 year: 2023 text: May 2023
PublicationDecade	2020
PublicationPlace	Hoboken, USA
PublicationPlace_xml	– name: Hoboken, USA – name: United States – name: Bethesda
PublicationTitle	Protein science
PublicationTitleAlternate	Protein Sci
PublicationYear	2023
Publisher	John Wiley & Sons, Inc Wiley Subscription Services, Inc
Publisher_xml	– name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc
References	2017; 6 2015; 34 2010; 10 2017; 8 2021; 64 2013; 69 2010; 19 2004; 25 1997; 276 2014; 24 2011; 54 2020; 12 2022; 65 2003; 278 2017; 114 2013; 9 2014; 20 2013; 19 2010; 66 2018; 9 2009; 52 2012; 134 2015; 137 2015; 40 2006; 440 2014; 57 2009; 16 2015; 16 2017; 60 2000; 28 2019; 75 2021; 223 2012; 1823 2016; 129 2015; 10 2017; 23 1993 2018; 61 2019; 141 2016; 16 2022; 238 2002; 27 2021; 54 2021; 12 2021; 11 2022; 61 2019; 87 2006; 49 2015; 112 2017; 12 2005; 5 2009; 9 2020; 117 2009; 388 2007; 40 2009; 4 2022; 11 2020; 21 2019; 294 2021; 60 2020; 1243 2012; 317 2018; 13 e_1_2_9_31_1 e_1_2_9_52_1 e_1_2_9_50_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_56_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_54_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_58_1 e_1_2_9_18_1 e_1_2_9_41_1 e_1_2_9_64_1 e_1_2_9_20_1 e_1_2_9_62_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_66_1 e_1_2_9_8_1 e_1_2_9_6_1 e_1_2_9_4_1 e_1_2_9_60_1 e_1_2_9_2_1 e_1_2_9_26_1 e_1_2_9_49_1 e_1_2_9_28_1 e_1_2_9_47_1 e_1_2_9_30_1 e_1_2_9_53_1 e_1_2_9_51_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_57_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_55_1 Hubbard S (e_1_2_9_23_1) 1993 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_59_1 e_1_2_9_19_1 e_1_2_9_42_1 e_1_2_9_63_1 e_1_2_9_40_1 e_1_2_9_61_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_67_1 e_1_2_9_44_1 e_1_2_9_65_1 e_1_2_9_7_1 e_1_2_9_5_1 e_1_2_9_3_1 e_1_2_9_9_1 e_1_2_9_25_1 e_1_2_9_27_1 e_1_2_9_48_1 e_1_2_9_29_1
References_xml	– volume: 87 start-page: 869 year: 2019 end-page: 77 article-title: Structures of Hsp90alpha and Hsp90beta bound to a purine‐scaffold inhibitor reveal an exploitable residue for drug selectivity publication-title: Proteins – volume: 11 year: 2022 article-title: Ligand binding remodels protein side‐chain conformational heterogeneity publication-title: elife – volume: 54 start-page: 3989 year: 2011 end-page: 4005 article-title: How well can fragments explore accessed chemical space? A case study from heat shock protein 90 publication-title: J Med Chem – volume: 9 start-page: 22 year: 2009 end-page: 30 article-title: Fragment‐based ligand discovery publication-title: Mol Interv – volume: 16 start-page: 287 year: 2009 end-page: 93 article-title: Dissection of the ATP‐induced conformational cycle of the molecular chaperone Hsp90 publication-title: Nat Struct Mol Biol – volume: 23 start-page: 15775 year: 2017 end-page: 82 article-title: Second generation Grp94‐selective inhibitors provide opportunities for the inhibition of metastatic cancer publication-title: Chemistry – volume: 13 start-page: 2522 year: 2018 end-page: 33 article-title: The recognition of unrelated ligands by individual proteins publication-title: ACS Chem Biol – volume: 12 start-page: 960 year: 2020 end-page: 8 article-title: Ligand design by targeting a binding site water publication-title: Chem Sci – volume: 57 start-page: 3382 year: 2014 end-page: 400 article-title: Identification of novel HSP90alpha/beta isoform selective inhibitors using structure‐based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease publication-title: J Med Chem – volume: 10 start-page: 2772 year: 2015 end-page: 84 article-title: The recognition of identical ligands by unrelated proteins publication-title: ACS Chem Biol – volume: 20 start-page: 275 year: 2014 end-page: 7 article-title: Stressing the development of small molecules targeting HSP90 publication-title: Clin Cancer Res – volume: 10 start-page: 537 year: 2010 end-page: 49 article-title: Targeting the dynamic HSP90 complex in cancer publication-title: Nat Rev Cancer – volume: 12 start-page: 11275 year: 2021 end-page: 93 article-title: Temperature artifacts in protein structures bias ligand‐binding predictions publication-title: Chem Sci – volume: 75 start-page: 861 year: 2019 end-page: 77 article-title: Macromolecular structure determination using X‐rays, neutrons and electrons: recent developments in Phenix publication-title: Acta Crystallogr D Struct Biol – volume: 21 start-page: 302 year: 2020 end-page: 17 article-title: Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014 publication-title: Curr Drug Targets – volume: 19 start-page: 1420 year: 2010 end-page: 31 article-title: Automated electron‐density sampling reveals widespread conformational polymorphism in proteins publication-title: Protein Sci – volume: 40 start-page: 658 year: 2007 end-page: 74 article-title: Phaser crystallographic software publication-title: J Appl Crystallogr – volume: 52 start-page: 4794 year: 2009 end-page: 809 article-title: Combining hit identification strategies: fragment‐based and in silico approaches to orally active 2‐aminothieno[2,3‐d]pyrimidine inhibitors of the Hsp90 molecular chaperone publication-title: J Med Chem – volume: 60 start-page: 10547 year: 2021 end-page: 51 article-title: Selective inhibition of the Hsp90α isoform publication-title: Angew Chem Int Ed Engl – volume: 114 start-page: E6839 year: 2017 end-page: 46 article-title: Testing inhomogeneous solvation theory in structure‐based ligand discovery publication-title: Proc Natl Acad Sci U S A – volume: 294 start-page: 16010 year: 2019 end-page: 9 article-title: NECA derivatives exploit the paralog‐specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90 publication-title: J Biol Chem – volume: 1823 start-page: 624 year: 2012 end-page: 35 article-title: The Hsp90 chaperone machinery: conformational dynamics and regulation by co‐chaperones publication-title: Biochim Biophys Acta – volume: 61 start-page: 2793 year: 2018 end-page: 805 article-title: Structure based design of a Grp94‐selective inhibitor: exploiting a key residue in Grp94 to optimize paralog‐selective binding publication-title: J Med Chem – volume: 61 year: 2022 article-title: Water networks repopulate protein‐ligand interfaces with temperature publication-title: Angew Chem Int Ed Engl – volume: 54 year: 2021 article-title: Macromolecular room temperature crystallography publication-title: Q Rev Biophys – volume: 9 start-page: 425 year: 2018 article-title: Structure‐guided design of an Hsp90β N‐terminal isoform‐selective inhibitor publication-title: Nat Commun – volume: 16 start-page: 1560 year: 2015 end-page: 4 article-title: One crystal, two temperatures: Cryocooling penalties Alter ligand binding to transient protein sites publication-title: Chembiochem – volume: 61 start-page: 5922 year: 2018 end-page: 5933 article-title: Paradoxically, most flexible ligand binds most entropy‐favored: intriguing impact of ligand flexibility and solvation on drug–kinase binding publication-title: J Med Chem – volume: 6 year: 2017 article-title: Symmetry broken and rebroken during the ATP hydrolysis cycle of the mitochondrial Hsp90 TRAP1 publication-title: elife – volume: 60 start-page: 6781 year: 2017 end-page: 827 article-title: The roles of water in the protein matrix: a largely untapped resource for drug discovery publication-title: J Med Chem – volume: 24 start-page: 204 year: 2014 end-page: 8 article-title: Correlation between chemotype‐dependent binding conformations of HSP90alpha/beta and isoform selectivity‐implications for the structure‐based design of HSP90alpha/beta selective inhibitors for treating neurodegenerative diseases publication-title: Bioorg Med Chem Lett – volume: 66 start-page: 486 year: 2010 end-page: 501 article-title: Features and development of Coot publication-title: Acta Crystallogr D Biol Crystallogr – volume: 69 start-page: 150 year: 2013 end-page: 67 article-title: Techniques, tools and best practices for ligand electron‐density analysis and results from their application to deposited crystal structures publication-title: Acta Crystallogr D Biol Crystallogr – volume: 49 start-page: 4953 year: 2006 end-page: 60 article-title: Structural and quantum chemical studies of 8‐aryl‐sulfanyl adenine class Hsp90 inhibitors publication-title: J Med Chem – volume: 16 start-page: 2779 year: 2016 end-page: 91 article-title: Paralog specific Hsp90 inhibitors—a brief history and a bright future publication-title: Curr Top Med Chem – year: 1993 – volume: 65 start-page: 13692 year: 2022 end-page: 704 article-title: Large‐scale ligand perturbations of the protein conformational landscape reveal state‐specific interaction hotspots publication-title: J Med Chem – volume: 238 year: 2022 article-title: Pan‐ and isoform‐specific inhibition of Hsp90: design strategy and recent advances publication-title: Eur J Med Chem – volume: 223 year: 2021 article-title: Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti‐inflammatory effects publication-title: Eur J Med Chem – volume: 19 start-page: 347 year: 2013 end-page: 65 article-title: The therapeutic target Hsp90 and cancer hallmarks publication-title: Curr Pharm Des – volume: 276 start-page: 307 year: 1997 end-page: 26 article-title: Processing of X‐ray diffraction data collected in oscillation mode publication-title: Methods Enzymol – volume: 9 start-page: 1436 year: 2009 end-page: 46 article-title: Purine‐scaffold Hsp90 inhibitors publication-title: Curr Top Med Chem – volume: 134 start-page: 9796 year: 2012 end-page: 804 article-title: Development of a Grp94 inhibitor publication-title: J Am Chem Soc – volume: 278 start-page: 48330 year: 2003 end-page: 8 article-title: Structure of the N‐terminal domain of GRP94. Basis for ligand specificity and regulation publication-title: J Biol Chem – volume: 1243 start-page: 135 year: 2020 end-page: 46 article-title: The right tool for the job: an overview of Hsp90 inhibitors publication-title: Adv Exp Med Biol – volume: 12 start-page: 244 year: 2017 end-page: 53 article-title: Transformation of the non‐selective Aminocyclohexanol‐based Hsp90 inhibitor into a Grp94‐Seletive scaffold publication-title: ACS Chem Biol – volume: 5 start-page: 761 year: 2005 end-page: 72 article-title: HSP90 and the chaperoning of cancer publication-title: Nat Rev Cancer – volume: 129 start-page: 51 year: 2016 end-page: 88 article-title: Anticancer inhibitors of Hsp90 function: beyond the usual suspects publication-title: Adv Cancer Res – volume: 137 start-page: 4358 year: 2015 end-page: 67 article-title: Development of a mitochondria‐targeted Hsp90 inhibitor based on the crystal structures of human TRAP1 publication-title: J Am Chem Soc – volume: 34 start-page: 60 year: 2015 end-page: 8 article-title: Assessing and maximizing data quality in macromolecular crystallography publication-title: Curr Opin Struct Biol – volume: 11 start-page: 1446 year: 2021 end-page: 68 article-title: The disruption of protein‐protein interactions with co‐chaperones and client substrates as a strategy towards Hsp90 inhibition publication-title: Acta Pharm Sin B – volume: 28 start-page: 235 year: 2000 end-page: 42 article-title: The Protein Data Bank publication-title: Nucleic Acids Res – volume: 27 start-page: 203 year: 2002 end-page: 8 article-title: Protein‐water interactions in a dynamic world publication-title: Trends Biochem Sci – volume: 64 start-page: 1545 year: 2021 end-page: 57 article-title: The development of Hsp90β‐selective inhibitors to overcome detriments associated with publication-title: J Med Chem – volume: 317 start-page: 61 year: 2012 end-page: 82 article-title: Hsp90 inhibitors and drugs from fragment and virtual screening publication-title: Top Curr Chem – volume: 117 start-page: 33204 year: 2020 end-page: 15 article-title: Assessment of enzyme active site positioning and tests of catalytic mechanisms through X‐ray‐derived conformational ensembles publication-title: Proc Natl Acad Sci U S A – volume: 112 start-page: 5039 year: 2015 end-page: 44 article-title: Homologous ligands accommodated by discrete conformations of a buried cavity publication-title: Proc Natl Acad Sci U S A – volume: 440 start-page: 1013 year: 2006 end-page: 7 article-title: Crystal structure of an Hsp90‐nucleotide‐p23/Sba1 closed chaperone complex publication-title: Nature – volume: 8 start-page: 2276 year: 2017 article-title: Protein conformational flexibility modulates kinetics and thermodynamics of drug binding publication-title: Nat Commun – volume: 141 start-page: 15818 year: 2019 end-page: 26 article-title: Water networks can determine the affinity of ligand binding to proteins publication-title: J Am Chem Soc – volume: 40 start-page: 117 year: 2015 end-page: 25 article-title: Hsp90 interaction with clients publication-title: Trends Biochem Sci – volume: 66 start-page: 125 year: 2010 end-page: 32 article-title: XDS publication-title: Acta Crystallogr D Biol Crystallogr – volume: 25 start-page: 1605 year: 2004 end-page: 12 article-title: UCSF chimera—A visualization system for exploratory research and analysis publication-title: J Comput Chem – volume: 388 start-page: 1033 year: 2009 end-page: 42 article-title: Different poses for ligand and chaperone in inhibitor‐bound Hsp90 and GRP94: implications for paralog‐specific drug design publication-title: J Mol Biol – volume: 4 start-page: 963 year: 2009 end-page: 6 article-title: Fragment‐based identification of Hsp90 inhibitors publication-title: ChemMedChem – volume: 9 start-page: 677 year: 2013 end-page: 84 article-title: Paralog‐selective Hsp90 inhibitors define tumor‐specific regulation of HER2 publication-title: Nat Chem Biol – ident: e_1_2_9_6_1 doi: 10.1002/cmdc.200900011 – ident: e_1_2_9_37_1 doi: 10.1039/D0SC04938G – ident: e_1_2_9_66_1 doi: 10.1073/pnas.2011350117 – ident: e_1_2_9_51_1 doi: 10.1021/acs.jmedchem.7b01608 – ident: e_1_2_9_33_1 doi: 10.1002/pro.423 – ident: e_1_2_9_38_1 doi: 10.1016/S0968-0004(02)02067-4 – ident: e_1_2_9_41_1 doi: 10.1021/acschembio.6b00747 – ident: e_1_2_9_31_1 doi: 10.1038/s41467-017-02013-1 – ident: e_1_2_9_24_1 doi: 10.1074/jbc.RA119.009960 – ident: e_1_2_9_45_1 doi: 10.1158/1078-0432.CCR-13-2571 – ident: e_1_2_9_54_1 doi: 10.1016/j.apsb.2020.11.015 – ident: e_1_2_9_12_1 doi: 10.1021/ja303477g – ident: e_1_2_9_50_1 doi: 10.1107/S0907444912044423 – ident: e_1_2_9_7_1 doi: 10.1093/nar/28.1.235 – ident: e_1_2_9_61_1 doi: 10.7554/eLife.74114 – ident: e_1_2_9_67_1 doi: 10.1016/j.ejmech.2022.114516 – ident: e_1_2_9_15_1 doi: 10.1016/j.bmcl.2013.11.036 – ident: e_1_2_9_34_1 doi: 10.1021/ja511893n – ident: e_1_2_9_8_1 doi: 10.1039/D1SC02751D – ident: e_1_2_9_10_1 doi: 10.1002/chem.201703398 – ident: e_1_2_9_58_1 doi: 10.1002/anie.202112919 – ident: e_1_2_9_48_1 doi: 10.1002/jcc.20084 – ident: e_1_2_9_16_1 doi: 10.1021/jm500042s – ident: e_1_2_9_4_1 doi: 10.1073/pnas.1703287114 – ident: e_1_2_9_19_1 doi: 10.1002/cbic.201500196 – ident: e_1_2_9_55_1 doi: 10.1074/jbc.M308661200 – ident: e_1_2_9_18_1 doi: 10.1124/mi.9.1.7 – ident: e_1_2_9_29_1 doi: 10.1016/j.tibs.2014.12.002 – ident: e_1_2_9_36_1 doi: 10.1107/S2059798319011471 – ident: e_1_2_9_59_1 doi: 10.2174/156802609789895737 – ident: e_1_2_9_2_1 doi: 10.1038/nature04716 – ident: e_1_2_9_13_1 doi: 10.7554/eLife.25235 – ident: e_1_2_9_57_1 doi: 10.1021/acs.jmedchem.2c00708 – ident: e_1_2_9_11_1 doi: 10.1021/jacs.9b06275 – ident: e_1_2_9_39_1 doi: 10.1107/S0021889807021206 – ident: e_1_2_9_21_1 doi: 10.2174/1568026616666160413141154 – ident: e_1_2_9_28_1 doi: 10.1107/S0907444909047337 – ident: e_1_2_9_25_1 doi: 10.1002/prot.25750 – ident: e_1_2_9_22_1 doi: 10.1038/nsmb.1565 – ident: e_1_2_9_5_1 doi: 10.1021/acschembio.5b00683 – ident: e_1_2_9_32_1 doi: 10.1007/978-3-030-40204-4_9 – ident: e_1_2_9_52_1 doi: 10.1007/128_2011_181 – ident: e_1_2_9_46_1 doi: 10.1016/S0076-6879(97)76066-X – ident: e_1_2_9_3_1 doi: 10.1038/s41467-017-02258-w – ident: e_1_2_9_35_1 doi: 10.1016/j.bbamcr.2011.09.003 – ident: e_1_2_9_40_1 doi: 10.1073/pnas.1500806112 – ident: e_1_2_9_63_1 doi: 10.1021/acs.jmedchem.8b00105 – ident: e_1_2_9_64_1 doi: 10.2174/1389450120666190829162544 – ident: e_1_2_9_65_1 doi: 10.1016/j.ejmech.2021.113604 – ident: e_1_2_9_14_1 doi: 10.1107/S0907444910007493 – ident: e_1_2_9_17_1 doi: 10.1017/S0033583520000128 – volume-title: NACCESS, computer program year: 1993 ident: e_1_2_9_23_1 – ident: e_1_2_9_30_1 doi: 10.1016/j.sbi.2015.07.003 – ident: e_1_2_9_47_1 doi: 10.1038/nchembio.1335 – ident: e_1_2_9_26_1 doi: 10.1021/jm060297x – ident: e_1_2_9_43_1 doi: 10.1021/acs.jmedchem.0c01700 – ident: e_1_2_9_53_1 doi: 10.1021/jm200350g – ident: e_1_2_9_60_1 doi: 10.1038/nrc2887 – ident: e_1_2_9_42_1 doi: 10.1002/anie.202015422 – ident: e_1_2_9_44_1 doi: 10.2174/138161213804143725 – ident: e_1_2_9_27_1 doi: 10.1016/j.jmb.2009.03.071 – ident: e_1_2_9_20_1 doi: 10.1016/bs.acr.2015.12.001 – ident: e_1_2_9_56_1 doi: 10.1021/acs.jmedchem.7b00057 – ident: e_1_2_9_62_1 doi: 10.1038/nrc1716 – ident: e_1_2_9_49_1 doi: 10.1021/acschembio.8b00443 – ident: e_1_2_9_9_1 doi: 10.1021/jm900357y
SSID	ssj0004123
Score	2.4534051
Snippet	Isoforms of heat shock protein 90 (HSP90) fold oncoproteins that facilitate all 10 hallmarks of cancer. However, its promise as a therapeutic target remains...
SourceID	pubmedcentral proquest pubmed crossref wiley
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e4629
SubjectTerms	Antineoplastic Agents - chemistry Binding conformational flexibility Heat shock proteins HSP90 Heat-Shock Proteins - chemistry Hsp90 isoforms Hsp90 protein Humans Isoforms ligand binding Ligands pan‐Hsp90 inhibitors Protein Binding Protein Conformation Protein folding Protein Isoforms - chemistry Proteins Side effects Therapeutic targets water networks
Title	Pan‐HSP90 ligand binding reveals isoform‐specific differences in plasticity and water networks
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpro.4629 https://www.ncbi.nlm.nih.gov/pubmed/36938943 https://www.proquest.com/docview/2806809534 https://www.proquest.com/docview/2788801055 https://pubmed.ncbi.nlm.nih.gov/PMC10108437
Volume	32
WOSCitedRecordID	wos000973169800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1469-896X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0004123 issn: 0961-8368 databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1469-896X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004123 issn: 0961-8368 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtQwELWgRYIXLi2FpaUyEipPoXFsHOexKqyKVC1RobBvUXwJRCrearMF9Y1P6Df2SzrjXMqqICHxstEqk5sz9hw7Z84Q8pIbJ7iQOsq4hQlKgiQACCSRNBCdhbBxFSj_nw_TyURNp1nesSoxF6bVhxgW3LBnhPEaO3ipm91r0VAYYF4LmWS3ySpjXGHZhkTk1zmRLGnLyEsWKS5VLzwbJ7v9kcuh6Aa-vEmT_B2-hvgzfvA_d_6Q3O9QJ91r3eQRueX8Glnf8zDj_n5Od2jggYYF9jVyd7-vAbdOdF76y18XBx_zLKYn9dfSW6rrkAhDUfsJfJfWzQyBL5hh1iYyj2hfdQXGIFp7egoIHcnbi3OKJ_gJ8HZOfcs_bx6T4_G7T_sHUVeVITI4d4mcrqBFLER6y0vAW0wwVrkytTwFeKErJq3KNJNGybiSaaXNG2Oy1NnMacsryzfIip9595RQYTizMnaYzyoql-lEaKVEGdtEA7JJR-RV_4IK00mWY-WMk6IVW04KaMoCm3JEXgyWp61Mxx9stvp3XHQdtSnww7JCzT0Bpxh2Qyvjd5PSu9kZ2OAyQagkOiJPWpcYLsJlxlHCfkTUkrMMBijfvbzH19-CjDcMhrEKT7kTvOWvN17kRx9w--xfDTfJvQSwWMvL3CIri_mZe07umB-Luplvh34Cv-lUbZPVt0fj40P49-X95ArvnB3D
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB6VgtReCrRQFgoYCZVTaBK7jiNOVUW1FcuyggK9RfFP2kjFW-1uQb3xCDwjT8KMs0lZFSQkTjl44jj22PPZnvkG4Dk3TnAhdZRzixuUlJwA0JBE0qB1FsLGVXD5_zTIhkN1fJyPluBVGwvT8EN0B240M8J6TROcDqR3rlhDcYV5KWSa34CbAnEG5W34fDi8CopM0iaPvEwixaVqmWfjdKd9c9EWXQOY1_0kf8evwQAd3P6vpt-BtTnuZHuNotyFJefXYWPP4577yyXbZsETNByxr8PKfpsFbgP0qPQ_v__ofxjlMTurT0pvma5DKAwj9ifUXlZPxwR9UYziNsn3iLV5V3AVYrVn54jRyX17dsmogm8IcCfMNx7o03vw8eD10X4_mudliAztXiKnK-wSi7be8hIRVyKSpHJlZnmGAENXibQq14k0SsaVzCptdo3JM2dzpy2vLL8Py37s3QNgwvDEythRRKuoXK5ToZUSZWxTjdgm68GLdoQKMyctp9wZZ0VDt5wW2JUFdWUPnnWS5w1Rxx9kttpBLuZTdVrQ1bIi1j2BVXTF2Mt0c1J6N75AGTooCLlEe7DZ6ET3ES5zTiT2PVAL2tIJEIH3YomvTwORNy6HsQp_uR3U5a8NL0bv39Hz4b8KPoWV_tHbQTE4HL55BKspIrPGS3MLlmeTC_cYbpmvs3o6eRImzS8oPx6E
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VLQIuPFoeCwWMhMopbRIbJxGnqmVVxGqJCkW9RfEjEKl4V7tbUG_8BH4jv4QZ51FWBQmJUw6eOI499ny2Z74BeM61FVxIFWTc4AYlJicANCSB1GidhTBh5V3-P46TySQ9OcnyNXjVxcI0_BD9gRvNDL9e0wS3M1PtXrCG4gqzI2ScXYF1QTlkBrB-cDQ6Hl-ERUZxk0leRkHKZdpxz4bxbvfuqjW6BDEve0r-jmC9CRrd-q_G34abLfJke42q3IE16zZgc8_hrvvLOdtm3hfUH7JvwPX9Lg_cJqi8dD-__zh8n2chO60_lc4wVftgGEb8T6i_rF5MCfyiGEVukvcR6zKv4DrEasdmiNLJgXt5zqiCbwhx58w1PuiLu3A8ev1h_zBoMzMEmvYvgVUVdolBa294iZgrElFU2TIxPEGIoapImjRTkdSpDCuZVEq_1DpLrMmsMrwy_B4M3NTZB8CE5pGRoaWYVlHZTMVCpakoQxMrRDfJEF50I1TolracsmecFg3hclxgVxbUlUN41kvOGqqOP8hsdYNctJN1UdDlckq8ewKr6Iuxl-nupHR2eoYydFTgs4kO4X6jE_1HuMw40dgPIV3Rll6AKLxXS1z92VN544IYpv4vt726_LXhRX70jp4P_1XwKVzLD0bF-M3k7SO4ESM0a9w0t2CwnJ_Zx3BVf13Wi_mTdtb8AgNuHy0
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pan%E2%80%90HSP90+ligand+binding+reveals+isoform%E2%80%90specific+differences+in+plasticity+and+water+networks&rft.jtitle=Protein+science&rft.au=Stachowski%2C+Timothy+R&rft.au=Nithianantham%2C+Stanley&rft.au=Vanarotti%2C+Murugendra&rft.au=Lopez%2C+Karlo&rft.date=2023-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0961-8368&rft.eissn=1469-896X&rft.volume=32&rft.issue=5&rft_id=info:doi/10.1002%2Fpro.4629&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0961-8368&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0961-8368&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0961-8368&client=summon